Biperiden Challenge Model in Healthy Elderly as Proof‐of‐Pharmacology Tool: A Randomized, Placebo‐Controlled Trial

Selective M(1) muscarinic acetylcholine receptor (mAChR) agonists are being developed as symptomatic treatment for neurodegenerative and neuropsychiatric disorders that lead to cognitive dysfunction. Demonstrating cognition‐enhancing effects in early‐phase clinical development in healthy subjects is...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakker, Charlotte, van Esdonk, Michiel J., Stuurman, Rik (F). E., Borghans, Laura G.J.M., de Kam, Marieke L., van Gerven, Joop M.A., Groeneveld, Geert Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Drug Development
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596596/
https://www.ncbi.nlm.nih.gov/pubmed/34021607
http://dx.doi.org/10.1002/jcph.1913

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596596/
https://www.ncbi.nlm.nih.gov/pubmed/34021607
http://dx.doi.org/10.1002/jcph.1913

Ejemplares similares